Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Novel conditioning regimen in upfront autologous stem cell transplantation in high-risk DLBCL

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Comparison of OS and PFS between the different groups.

References

  1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5. https://doi.org/10.1056/nejm199512073332305.

    Article  CAS  PubMed  Google Scholar 

  2. Bosly A, Coiffier B, Gisselbrecht C, Tilly H, Auzanneau G, Andrien F, et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol. 1992;10:1615–23. https://doi.org/10.1200/jco.1992.10.10.1615.

    Article  CAS  PubMed  Google Scholar 

  3. Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, et al. Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas. J Clin Oncol. 2016;34:4015–22. https://doi.org/10.1200/jco.2016.67.2980.

    Article  CAS  PubMed  Google Scholar 

  4. Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017;18:1076–88. https://doi.org/10.1016/s1470-2045(17)30444-8.

    Article  CAS  PubMed  Google Scholar 

  5. Shi Y, Liu P, Zhou S, Yang J, Han X, He X, et al. Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity. Asia Pac J Clin Oncol. 2017;13:e423–e429. https://doi.org/10.1111/ajco.12610.

    Article  PubMed  Google Scholar 

  6. Engert A, Schnell R, Küpper F, Reiser M, Engelhard M, Wilhelm M, et al. A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin’s lymphoma. Leuk Lymphoma. 1997;24:513–22. https://doi.org/10.3109/10428199709055588.

    Article  CAS  PubMed  Google Scholar 

  7. Tian C, Li Y, Liu S, Chen Z, Zhang Y, Yu Y, et al. Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients. Sci Rep. 2021;11:4273 https://doi.org/10.1038/s41598-021-81944-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, et al. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:688–97. https://doi.org/10.1016/j.bbmt.2005.05.014.

    Article  CAS  PubMed  Google Scholar 

  9. Galieni P, Troiani E, Bigazzi C, Mazzotta S, Ruggieri M, Pezzoni V, et al. Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018;53:91–93. https://doi.org/10.1038/bmt.2017.206.

    Article  CAS  PubMed  Google Scholar 

  10. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol–a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol. 2000;18:3025–30. https://doi.org/10.1200/jco.2000.18.16.3025.

    Article  CAS  PubMed  Google Scholar 

  11. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013;369:1681–90. https://doi.org/10.1056/NEJMoa1301077.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Colita A, Colita A, Bumbea H, Croitoru A, Orban C, Lipan LE, et al. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective comparison of toxicity and efficacy on 222 patients in the first 100 days after transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. Front Oncol. 2019;9. https://doi.org/10.3389/fonc.2019.00892.

Download references

Acknowledgements

This work was supported by the Shanghai Science and Technology Committee (grant number: 21Y11909000), Shanghai Health Committee (grant number: 202140518), the Elite Project of Huadong hospital (HD1439).

Author information

Authors and Affiliations

Authors

Contributions

JM and YX were responsible for developing the conceptual framework of the study, designing and writing the protocol. JM, HY, and SS collected and analyzed data, conducted experiments, wrote and reviewed the paper. PC, MC, LS, MW, WQ, and WF conducted experiments. ZH contributed to the technical support. The authors read and approved the final manuscript.

Corresponding authors

Correspondence to Jiexian Ma or Yanhui Xie.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, J., Sun, S., Hu, Y. et al. Novel conditioning regimen in upfront autologous stem cell transplantation in high-risk DLBCL. Bone Marrow Transplant 57, 1612–1614 (2022). https://doi.org/10.1038/s41409-022-01766-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-022-01766-8

Search

Quick links